These data are consistent with the lack of efficacy of MEK inhibitors as a single agent in advanced CRC carrying KRAS mutation (in both preclinical and clinical situations) as we would predict that inhibition of MEK would only work at a much earlier stage of tumourigenesis (e.g. during dedifferentiation). Here, MAP2K7 is linked to colorectal carcinoma.